Stock listing
NASDAQ:CTY City Therapeutics, Inc. Stock
Home listing (NASDAQ) of City Therapeutics, Inc.
Follow City Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CTY
$19.32 USD +2.68 (+16.1%)
Close on Nov 20, 2026
- Day range
- $16.96 – $20.62 USDNov 20, 2026
- Volume
- 250,121 sharesNov 20, 2026
- Market cap
- $972.4M USDAt the close on Nov 20, 2026 · price × 50.33M shares outstanding
- Traded on an average day
- $6.56M USDMedian day 275,529 shares · last 3 months, Oct 16, 2026 – Nov 20, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CTY · Home | $19.32 USD | +2.68 (+16.1%) | 250,121 | $18.35 | $20.62 | $16.96 | $16.64 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Oct 16, 2026 – Nov 20, 2026 · NASDAQ:CTY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $19.32 | +2.68 | +16.1% | $18.35 | $20.62 | $16.96 | 250,121 | |
| $16.64 | -0.86 | -4.9% | $17.51 | $18.76 | $16.26 | 252,983 | |
| $17.50 | +0.52 | +3.1% | $16.96 | $17.69 | $16.43 | 321,270 | |
| $16.98 | -1.12 | -6.2% | $18.11 | $18.11 | $16.69 | 238,266 | |
| $18.10 | -0.88 | -4.6% | $18.77 | $20.33 | $16.93 | 482,372 | |
| $18.98 | +1.97 | +11.6% | $16.96 | $19.43 | $16.65 | 214,891 | |
| $17.01 | -2.61 | -13.3% | $19.65 | $21.31 | $16.21 | 458,676 | |
| $19.62 | +0.95 | +5.1% | $19.18 | $19.76 | $18.94 | 423,475 | |
| $18.67 | +0.42 | +2.3% | $18.30 | $18.85 | $17.88 | 245,189 | |
| $18.25 | +1.18 | +6.9% | $17.95 | $18.56 | $17.49 | 311,818 | |
| $17.07 | +0.66 | +4.0% | $16.28 | $17.32 | $15.81 | 209,635 | |
| $16.41 | -2.68 | -14.0% | $19.37 | $20.07 | $16.22 | 359,719 | |
| $19.09 | -1.79 | -8.6% | $21.12 | $21.12 | $18.77 | 275,529 | |
| $20.88 | +0.17 | +0.8% | $21.08 | $22.65 | $20.39 | 224,372 | |
| $20.71 | -1.43 | -6.5% | $22.08 | $22.26 | $20.37 | 116,775 | |
| $22.14 | +0.49 | +2.3% | $21.63 | $22.35 | $21.54 | 130,916 | |
| $21.65 | +0.79 | +3.8% | $20.89 | $21.96 | $20.50 | 335,293 | |
| $20.86 | +0.07 | +0.3% | $20.79 | $21.59 | $20.70 | 214,807 | |
| $20.79 | +0.02 | +0.1% | $20.62 | $21.31 | $20.30 | 136,056 | |
| $20.77 | 0.00 | 0.0% | $20.62 | $21.14 | $20.03 | 343,835 | |
| $20.77 | +0.34 | +1.7% | $20.41 | $20.88 | $19.75 | 127,600 | |
| $20.43 | -0.40 | -1.9% | $20.78 | $21.69 | $19.97 | 283,100 | |
| $20.83 | -0.63 | -2.9% | $21.44 | $21.50 | $20.00 | 632,800 | |
| $21.46 | -0.94 | -4.2% | $21.94 | $22.00 | $21.03 | 302,400 | |
| $22.40 | — | — | $23.00 | $23.88 | $20.50 | 1,406,100 |
- Ticker
- NASDAQ:CTY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease
Latest news
City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease
Nov 10, 2026
Closed $19.62 (+5.1%) on Nov 10, 2026
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
Nov 4, 2026
Closed $16.41 (-14.0%) on Nov 4, 2026
City Therapeutics to Present at Upcoming November Investor Conferences
Nov 3, 2026
Closed $19.09 (-8.6%) on Nov 3, 2026
City Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 4 in the last 12 months · 4 in all · newest Nov 10, 2026 · oldest 2026
Where City Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CTY · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CTY | BOATS | United States | USD |
Valuation
EV/sales 59.2× against a median of 8.6×: 5th lowest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $802.8M USD
- P/E
- Loss
- EV/sales
- 59.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Not reported
- Operating margin
- −441.8%
- Net margin
- −431.4%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| City Therapeutics, Inc. · NASDAQ:CTY | US$972.4M | US$802.8M | n/a | 59.2× | n/a | n/a | −431.4% | n/a | n/a |
| Alto Neuroscience, Inc. · NYSE:ANRO | US$1.02B | US$711.7M | n/a | n/a | n/a | 3.4× | n/a | 0.1× | 1.65 |
| Inhibrx Biosciences, Inc. · NASDAQ:INBX | US$1.02B | US$1.09B | n/a | 546× | n/a | n/a | n/a | n/a | 1.89 |
| Duality Biotherapeutics, Inc. · HKEX:9606 | US$992.3M | US$609.0M | n/a | 4.8× | n/a | 4.6× | −170.8% | 0.3× | n/a |
| Peptron, Inc. · KRX:087010 | US$985.3M | US$948.0M | n/a | 211× | n/a | 10.2× | −342.2% | 0.2× | n/a |
| Omeros Corporation · NASDAQ:OMER | US$983.7M | US$920.3M | 10.0× | 12.4× | n/a | n/a | 132.3% | n/a | 1.64 |
| Everest Medicines Ltd. · HKEX:1952 | US$981.5M | US$1.00B | n/a | 2.8× | 183× | 1.3× | −2.2% | 0.4× | n/a |
| HBM Holdings Ltd. · HKEX:2142 | US$981.4M | US$711.5M | 10.7× | 4.5× | 8.6× | 2.4× | 57.8% | 0.2× | n/a |
| Seaport Therapeutics, Inc. · NASDAQ:SPTX | US$966.2M | US$675.8M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 0.72 |
| MoonLake Immunotherapeutics · NASDAQ:MLTX | US$942.1M | US$543.7M | n/a | n/a | n/a | 2.5× | n/a | 0.3× | 1.32 |
| Savara, Inc. · NASDAQ:SVRA | US$939.9M | US$840.4M | n/a | n/a | n/a | 8.7× | n/a | 0.3× | 1.42 |
| Median of the others | US$982.6M | US$776.1M | 10.4× | 8.6× | 95.9× | 3.0× | −2.2% | 0.2× | 1.53 |
Team and board
Officers
| Officer | Role |
|---|---|
| Andy Orth | Chief Executive Officer |
| Keith Regnante | Chief Financial Officer |
| Sebastian Trousil | Chief Operating Officer |
| Mary Beth DeLena | Chief Legal Officer and Secretary |
| Ari Nowacek | SVP, Corporate Development |
| Anna O’Driscoll | Chief Human Resources Officer |
| Baisong Mei | Chief Medical Officer |
| John Maraganore | Executive Chair |
| Tracy Zimmermann | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| John Maraganore | Executive Chair |
| Barry Greene | Board Director |
| Robert Nelsen | Board Director |
| Ron Philip | Board Director |
| Sara Nochur | Board Director |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$230M raised · US$18 a share · Goldman Sachs & Co. LLC +3 Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), Stifel (co-lead), Oppenheimer & Co. (co-lead) | Oct 19, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Oct 15, 2026.
- Price
- US$18.00 a share
- Shares offered
- 11,111,111 shares of common stock
- Offering size
- US$200 million
- Underwriters' option
- Up to 1,666,666 more shares
- Listing
- CTY on the Nasdaq Global Market
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, Stifel, Oppenheimer & Co. · In the order on the cover
- Shares delivered
- On or about Oct 19, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 15, 2026 |
| Filed publicly | Sep 24, 2026 |
| Amended once | Oct 9, 2026 |
| Shares registered with an exchange | Oct 13, 2026 |
| Declared effective by the SEC | Oct 15, 2026 |
| Final prospectus, with the price | Oct 16, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 16, 2026 |
| EFFECT · Notice that a registration is effective | Oct 15, 2026 |
| S-1MEF · Registration of more shares for the same offering | Oct 15, 2026 |
| CERT · Exchange's certificate of listing | Oct 15, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 13, 2026 |
| S-1/A · Registration statement, amended | Oct 9, 2026 |
| S-1 · Registration statement | Sep 24, 2026 |
| DRS/A · Draft registration statement, amended | Aug 24, 2026 |
| DRS · Draft registration statement | Jul 15, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 16, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.6M | 2.78M | 8.16B | 8.49B | 8.55B | 8.91B | 8.96B | 8.84B | 8.75B | 8.85B |
| Cost of revenue | 2.44B | 2.77B | 2.88B | 2.93B | 2.87B | 2.88B | 2.79B | 2.87B | ||
| Gross profit | 5.72B | 5.73B | 5.67B | 5.98B | 6.09B | 5.96B | 5.96B | 5.98B | ||
| Research and development | 58.4M | 25.7M | ||||||||
| Selling, general and administrative | 15.1M | 6.19M | 659.0M | 799.0M | 925.0M | 1.02B | 1.01B | 1.09B | 1.06B | 1.17B |
| Operating income | -59.9M | -29.1M | 2.88B | 2.66B | 2.31B | 2.32B | 2.26B | 2.11B | 2.08B | 1.91B |
| Depreciation and amortization | 1.17M | 424.0K | 1.36B | 1.44B | 1.58B | 1.68B | 1.84B | 1.97B | 2.08B | 2.23B |
| EBITDA | -58.8M | -28.7M | 4.25B | 4.10B | 3.89B | 4.00B | 4.10B | 4.08B | 4.15B | 4.13B |
| Interest expense | 2.26M | 448.0K | 448.0M | 465.0M | 478.0M | 473.0M | 464.0M | 450.0M | 443.0M | |
| Income before tax | -58.5M | -27.8M | 2.47B | 2.16B | 1.79B | 1.76B | 1.73B | 1.61B | 1.57B | 1.39B |
| Income tax | 641.0M | 494.0M | 134.0M | 678.0M | 659.0M | 639.0M | 602.0M | 542.0M | ||
| Net income | -58.5M | -27.8M | 1.83B | 1.67B | 1.66B | 1.08B | 1.07B | 970.0M | 964.0M | 849.0M |
| Earnings per share, basic | -1.21 | -0.58 |
Balance sheet
| Line | FY2025 | FY2024 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 112.8M | 126.9M | 2.00M | 5.00M | 1.00M | 5.00M | 3.00M | 6.00M | 14.0M | 8.00M |
| Receivables | 1.21M | 1.35M | 514.0M | 546.0M | 646.0M | 700.0M | 688.0M | 740.0M | 738.0M | 709.0M |
| Current assets | 116.9M | 128.9M | 2.49B | 1.85B | 1.77B | 1.71B | 1.60B | 1.85B | 1.75B | 1.57B |
| Goodwill | 9.36B | 9.36B | 9.36B | 9.35B | 9.35B | 9.35B | 9.35B | 9.37B | ||
| Total assets | 149.8M | 145.4M | 21.0B | 20.6B | 20.9B | 21.1B | 21.5B | 22.5B | 16.0B | 16.7B |
| Accounts payable | 2.69M | 2.34M | 403.0M | 441.0M | 317.0M | 398.0M | 369.0M | 464.0M | 440.0M | 456.0M |
| Current liabilities | 38.0M | 20.7M | 3.41B | 2.27B | 2.20B | 2.80B | 2.42B | 2.26B | 2.70B | 2.83B |
| Long-term debt | 31.1M | |||||||||
| Total debt | 5.95B | 5.96B | 7.28B | 7.26B | 7.24B | 7.38B | 7.56B | 7.63B | ||
| Total liabilities | 234.4M | 174.8M | 10.9B | 10.7B | 11.5B | 12.5B | 12.6B | 13.3B | 13.6B | 14.0B |
| Shareholders' equity | -84.7M | -29.4M | 10.1B | 9.87B | 9.34B | 8.69B | 8.91B | 9.18B | 9.61B | 9.97B |
| Shares outstanding | 48.4M | 48.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -41.6M | -20.4M | 3.33B | 3.79B | 2.44B | 2.65B | 2.59B | 2.80B | 2.71B | 2.77B |
| Capital spending | -2.40M | -3.54M | -1.05B | -1.04B | -1.33B | -1.26B | -1.25B | -1.17B | -1.26B | -1.27B |
| Free cash flow | -44.0M | -23.9M | 2.28B | 2.75B | 1.11B | 1.39B | 1.34B | 1.64B | 1.45B | 1.51B |
| Cash from investing | -1.72B | -1.15B | -1.44B | -1.33B | -1.22B | -1.25B | -1.38B | -1.53B | ||
| Cash from financing | 30.9M | 149.4M | -1.61B | -2.63B | -1.00B | -1.32B | -1.37B | -1.56B | -1.33B | -1.24B |
| Dividends paid | -1.60B | -1.27B | -1.00B | -1.30B | -1.35B | -1.40B | -1.32B | -1.15B | ||
| Share buybacks | -2.00M | -5.00M | -1.00M | -5.00M | -3.00M | -6.00M | -14.0M | -8.00M | ||
| Change in cash | -13.1M | 125.7M | -5.00M | 2.00M | -4.00M | 2.00M | -3.00M | -8.00M | 6.00M | 5.00M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 22, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
All 34 filings
Cap table
Built by 6ix from City Therapeutics, Inc.’s releases · as of Oct 19, 2026
- Common shares
- 50,332,279
- Fully diluted
- 50,332,279
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 50,332,279 | Oct 19, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 19, 2026 | 50,332,279 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Nelsen Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026) | Board Director · Since at least Oct 19, 2026 |
| Baisong Mei | Chief Medical Officer · Since at least Nov 4, 2026 |
| John Maraganore | Executive Chair · Since at least Oct 19, 2026 |
Log in to ask 6ix AI your own questions about City Therapeutics, Inc.